Although the simultaneous therapeutic blockade of orthosteric and allosteric inhibitors has shown anti-tumor activity against BCR-ABL1 point mutants and suppressed the emergence of resistant point mutations in vivo [18,19], structural studies have revealed that dual treatment with imatinib results in an energetically frustrated ABL structure. The gene discussed is ABL1; the disease is neoplasm.